Treatment of adipocytes
The present disclosure provides compositions comprising a lyn kinase activator and TRPM8 agonist, and to methods of: reducing blood glucose levels, weight gain, or fat depot levels; treating metabolic syndrome, Syndrome X, obesity, prediabetes, type II diabetes, type I diabetes; treating hypercholesterolemia, hypertension, coronary heart disease, diabetic neuropathy, lipodystrophy, diabetic retinopathy, erectile dysfunction, kidney disease, dyslipidemia, dyslipoproteinemia, a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, or pancreatitis; inducing the beiging of adipocytes; and preventing pancreatic beta cell degeneration.
1. A method of reducing blood glucose levels, weight gain, or fat depot levels, or treating metabolic syndrome, Syndrome X, obesity, prediabetes, type II diabetes, type I diabetes, hypercholesterolemia, dyslipidemia, or inducing the beiging of adipocytes, or preventing pancreatic beta cell degeneration in a mammal in need thereof, comprising administering to the mammal an effective amount of a lyn kinase activator and a TRPM8 agonist;
wherein the lyn kinase activator is of formula:
or a pharmaceutically acceptable salt thereof; and
the TRPM8 agonist is menthol.
2. The method of claim 1 , wherein the lyn kinase activator and TRPM8 agonist are present in the same composition.
3. A method of inducing the beiging of adipocytes or preventing pancreatic beta cell degeneration in a mammal in need thereof, comprising administering to the mammal an effective amount of a lyn kinase activator and a TRPM8 agonist, wherein the lyn kinase activator is of formula:
or a pharmaceutically acceptable salt thereof; and
the TRPM8 agonist is menthol.
4. The method of claim 3 , wherein the lyn kinase activator and TRPM 8 agonist are present in the same composition.
5. The method of claim 3 , wherein the method is for preventing pancreatic beta cell degeneration in a mammal in need thereof.